Ligand Pharmaceuticals (LGND) Cash & Current Investments (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Cash & Current Investments data on file, last reported at $779.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 273.1% year-over-year to $779.4 million; the trailing twelve-month figure through Mar 2026 stood at $779.4 million (up 273.1% YoY), and the FY2025 full-year result was $733.5 million, up 186.35% from the prior year.
• Cash & Current Investments improved to $779.4 million in Q1 2026, from $733.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $779.4 million in Q1 2026 to a low of $38.3 million in Q2 2024.
• A 5-year average of $285.8 million and a median of $211.9 million in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments plunged 82.52% in 2024 and soared 788.97% in 2025, its largest moves.
• Tracing LGND's Cash & Current Investments over 5 years: stood at $211.9 million in 2022, then declined by 19.62% to $170.3 million in 2023, then jumped by 50.41% to $256.2 million in 2024, then soared by 186.35% to $733.5 million in 2025, then rose by 6.26% to $779.4 million in 2026.
• Business Quant data shows LGND's Cash & Current Investments at $779.4 million in Q1 2026, $733.5 million in Q4 2025, and $664.5 million in Q3 2025.